Bridgefront Capital’s AbbVie ABBV Stock Holding History

Bridgefront Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,963	Closed	-$1.38M	–	493
2025 Q3	$1.38M	Sell	5,963 -6,779	-53%	-$1.38M	0.41%	45
2025 Q2	$2.37M	Buy	+12,742	New	+$2.37M	0.63%	11
2023 Q4	–	Sell	-4,757	Closed	-$709K	–	349
2023 Q3	$709K	Sell	4,757 -5,490	-54%	-$806K	0.5%	30
2023 Q2	$1.38M	Buy	+10,247	New	+$1.5M	0.75%	6
2023 Q1	–	Sell	-3,339	Closed	-$540K	–	405
2022 Q4	$540K	Buy	+3,339	New	+$512K	0.38%	80
2022 Q1	–	Sell	-4,613	Closed	-$625K	–	252
2021 Q4	$625K	Buy	+4,613	New	+$545K	0.61%	30
2021 Q3	–	Sell	-3,309	Closed	-$373K	–	298
2021 Q2	$373K	Buy	+3,309	New	+$373K	0.14%	268
2021 Q1	–	Sell	-8,114	Closed	-$869K	–	641
2020 Q4	$869K	Buy	+8,114	New	+$780K	0.3%	78

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bridgefront Capital's ABBV Position: Q4 2025 in Review

Bridgefront Capital sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 5,963 shares — an estimated $1.38M sold.

Bridgefront Capital first reported a position in ABBV in Q4 2020 and held it in 8 quarters. The position peaked at $2.37M in Q2 2025. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Bridgefront Capital reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
Bridgefront Capital sold 5,963 AbbVie shares in Q4 2025, an estimated $1.38M.
Bridgefront Capital first reported a position in AbbVie in Q4 2020 and held it in 8 quarters.
Bridgefront Capital's AbbVie position peaked at $2.37M in Q2 2025.
4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.